Linda Liau

Q: What Schools Are Affiliated With Linda Liau

Linda Liau is affiliated with the following schools: University of California, Los Angeles, University of Toronto

Linda Liau's AcademicInfluence.com Rankings

Linda Liau

Biology

#4123

World Rank

#6196

Historical Rank

Neuroscience

#789

World Rank

#823

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Linda Liau Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Linda M. Liau is an American neurosurgeon, neuroscientist, and the W. Eugene Stern Chair of the Department of Neurosurgery at the David Geffen School of Medicine at UCLA. Liau was elected to the Society of Neurological Surgeons in 2013 and the National Academy of Medicine in 2018. She has published over 230 research articles and a textbook, Brain Tumor Immunotherapy. She served as editor-in-chief of the Journal of Neuro-Oncology from 2007 to 2017.

(See a Problem?)

Linda Liau's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2009) (3374)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. (2005) (1455)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma (2007) (1052)
High-throughput oncogene mutation profiling in human cancer (2007) (1041)
Subgroup-specific structural variation across 1,000 medulloblastoma genomes (2012) (760)
Gene Expression Profiling of Gliomas Strongly Predicts Survival (2004) (735)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma (2018) (711)
Intertumoral Heterogeneity within Medulloblastoma Subgroups. (2017) (703)
The whole-genome landscape of medulloblastoma subtypes (2017) (658)
Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma (2008) (568)
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment (2005) (484)
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. (2011) (455)
Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. (2005) (441)
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. (2011) (410)
Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy (2010) (378)
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. (2013) (362)
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target (2006) (357)
Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain (2006) (345)
Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies (2010) (338)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (321)
Gene expression profiling identifies molecular subtypes of gliomas (2003) (312)
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation (2013) (300)
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. (2012) (290)
Identification of molecular subtypes of glioblastoma by gene expression profiling (2003) (280)
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles (2013) (276)
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy (2012) (265)
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers (2009) (257)
Cytogenetic prognostication within medulloblastoma subgroups. (2014) (242)
Primary Glioblastomas Express Mesenchymal Stem-Like Properties (2006) (235)
Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma (2009) (234)
Bevacizumab and chemotherapy for recurrent glioblastoma (2009) (230)
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy (2009) (229)
Distinct transcription profiles of primary and secondary glioblastoma subgroups. (2006) (213)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2010) (209)
Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age (2008) (206)
The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity1 (2006) (195)
Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. (2008) (182)
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. (2002) (174)
Probabilistic Radiographic Atlas of Glioblastoma Phenotypes (2013) (165)
Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells (2008) (160)
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (149)
Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. (2008) (148)
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma (2013) (146)
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. (2008) (146)
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma (2016) (145)
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. (2013) (143)
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. (2013) (138)
Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients (2017) (136)
Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors (2009) (135)
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma (2017) (133)
Identification of a human glioma-associated growth factor gene, granulin, using differential immuno-absorption. (2000) (128)
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. (2016) (127)
Genomic Landscape of Meningiomas (2009) (120)
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC (2018) (120)
PD-1 blockade enhances the vaccination-induced immune response in glioma. (2016) (118)
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. (2003) (118)
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation (2010) (109)
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2 (2007) (107)
Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II–III diffuse gliomas (2017) (104)
Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients (2013) (104)
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. (2013) (103)
Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides (2000) (101)
A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. (2010) (99)
The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine1 (2005) (93)
Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients (2012) (92)
Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone (2009) (86)
Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. (2009) (83)
pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. (2015) (82)
Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. (2012) (79)
Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. (2004) (79)
Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI (2013) (79)
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition (2004) (75)
Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. (2013) (73)
Detection of immune responses after immunotherapy in glioblastoma using PET and MRI (2017) (71)
Large-scale assessment of the gliomasphere model system. (2016) (69)
Heterogeneity within the PF-EPN-B ependymoma subgroup (2018) (69)
Management of low-grade glioma: a systematic review and meta-analysis. (2018) (68)
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy (2016) (66)
NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain1 (2006) (65)
Bioluminescent imaging of melanoma in live mice. (2005) (61)
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain (2008) (59)
Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. (2002) (57)
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. (2012) (56)
Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence (2013) (56)
IDH mutations in human glioma. (2012) (55)
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. (2000) (54)
NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) (2015) (54)
TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination (2016) (53)
Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. (2008) (52)
NF1 mutation drives neuronal activity-dependent initiation of optic glioma (2021) (52)
Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma (2021) (50)
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients (2015) (50)
Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist (1991) (49)
Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF-κB (2010) (49)
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities (2018) (48)
Simulation, phantom validation, and clinical evaluation of fast pH‐weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST‐EPI) in glioma at 3 T (2016) (46)
Immunology and Immunotherapy in Neurosurgical Disease (2003) (46)
Dendritic cell vaccines for brain tumors. (2010) (45)
Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. (2018) (44)
HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. (2015) (43)
Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures (2010) (42)
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation (2018) (42)
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma (2014) (42)
Contrast‐enhancing tumor growth dynamics of preoperative, treatment‐naive human glioblastoma (2016) (42)
Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. (2013) (41)
The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells (2014) (40)
Cellular immunity and immunotherapy of brain tumors. (2004) (39)
Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (38)
Cellular and vaccine therapeutic approaches for gliomas (2010) (38)
Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma (2017) (37)
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. (2012) (37)
Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. (2020) (36)
Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway (2011) (36)
Gliomas: advances in molecular analysis and characterization. (2005) (36)
Brain Tumor Immunotherapy (2000) (35)
Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. (2016) (35)
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide (2015) (34)
MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab (2015) (34)
Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. (2005) (34)
Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas (2014) (32)
Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications (2006) (31)
Simultaneous pH‐sensitive and oxygen‐sensitive MRI of human gliomas at 3 T using multi‐echo amine proton chemical exchange saturation transfer spin‐and‐gradient echo echo‐planar imaging (CEST‐SAGE‐EPI) (2018) (31)
MART-1 adenovirus-transduced dendritic cell immunization in a murine model of metastatic central nervous system tumor (2003) (30)
Use of language mapping to aid in resection of gliomas in eloquent brain regions. (2012) (30)
Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas (2015) (30)
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. (2019) (29)
Mahaley Clinical Research Award: extent of glioma resection using low-field (0.2 T) versus high-field (1.5 T) intraoperative MRI and image-guided frameless neuronavigation. (2005) (29)
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry (2019) (27)
Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients (2014) (27)
Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12–Primed CD8+ T Cells in a Melanoma Model (2011) (27)
Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange (2016) (26)
Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment (2014) (26)
The transcriptional landscape of Shh medulloblastoma (2021) (26)
Current status of clinical trials for glioblastoma. (2006) (26)
Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures (2001) (25)
The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma (2020) (25)
pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma (2019) (25)
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma (2022) (23)
Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage (2013) (23)
Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study (2020) (22)
Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T (2019) (20)
Central Nervous System Tumor Immunity Generated by a Recombinant Listeria monocytogenes Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden (2006) (19)
Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma (2018) (19)
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. (2015) (18)
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. (2014) (18)
Essential Gene Pathways for Glioblastoma Stem Cells: Clinical Implications for Prevention of Tumor Recurrence (2011) (17)
Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies (2005) (16)
Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation (2018) (16)
Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis? (2017) (16)
Subgroup and subtype-specific outcomes in adult medulloblastoma (2021) (15)
Imaging biomarkers for antiangiogenic therapy in malignant gliomas. (2013) (15)
C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma (2014) (13)
Optical imaging for brain tissue characterization using relative fluorescence lifetime imaging (2013) (12)
Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas. (2012) (11)
Erratum: Genomic Landscape of Meningiomas (Brain Pathology (2010) 20 (751-762)) (2011) (11)
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (11)
Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. (2019) (11)
Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas (2017) (10)
Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. (2021) (10)
Dendritic cell immunotherapy for brain tumors (2015) (10)
High order diffusion tensor imaging in human glioblastoma. (2011) (10)
NK and CD 4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain 1 (2006) (10)
Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes (2020) (9)
Harnessing T-Cell Immunity to Target Brain Tumors (2008) (9)
Endogenous vaults and bioengineered vault nanoparticles for treatment of glioblastomas: implications for future targeted therapies. (2012) (9)
Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy? (2020) (9)
Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (2004) (9)
Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET (2021) (9)
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry (2017) (9)
adjuvant Treatment for Gliomas (2003) (9)
Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. (2017) (8)
Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma (2014) (8)
Human Astrocytes Exhibit Tumor Microenvironment-, Age-, and Sex-Related Transcriptomic Signatures (2021) (8)
Gene expression profiling identifies molecular subtypes of gliomas (2006) (8)
Cell-Based Immunotherapy of Gliomas. (2018) (8)
AT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584) (2014) (8)
Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma. (2021) (7)
GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients (2019) (7)
Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
Developing a Professionalism and Harassment Policy for Organized Neurosurgery (2021) (7)
The Aging Neurosurgeon: When Is Enough, Enough? Attitudes Toward Ceasing Practice and Testing in Late Career (2017) (7)
Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. (2020) (7)
Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM (2015) (7)
Neurosurgeons in 2020: the impact of gender on neurosurgical training, family planning, and workplace culture. (2021) (7)
Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant–Induced MIR148A Promoter Methylation (2018) (6)
1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine Treatment After Brain Irradiation Preserves Cognitive Function in Mice (2020) (6)
Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience (2020) (6)
Targeting Stem Cells in Brain Tumors (2006) (6)
Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas (2020) (6)
Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma (2020) (5)
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation (2019) (5)
Research report Robustness of gene expression profiling in glioma specimen samplings and derived cell lines (2005) (5)
Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden (2021) (5)
FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas (2021) (5)
NC-01ATTENTIONAL AND LANGUAGE FUNCTIONING IN ADULT PATIENTS WITH GLIOMA: A VOXEL-BASED LESION-SYMPTOM MAPPING STUDY. (2014) (5)
Maintenance of Certification: Perceptions and Attitudes of Neurosurgeons (2018) (4)
Detection of 2-hydroxyglutarate in Mutant Brain Tumors in vivo using Proton Magnetic Resonance Spectroscopy (2011) (4)
IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION. (2014) (4)
Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients (2012) (4)
Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas (2020) (4)
Molecular characterization of brain tumors. (2004) (4)
Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas (2020) (4)
Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series (2019) (4)
Tumor suppressive miR-148 a is silenced by CpG island hypermethylation in IDH 1 mutant gliomas (2014) (4)
Prediction of GBM outcome using combined analysis of MGMT protein expression and promoter methylation. (2011) (4)
Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI (2022) (3)
ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL (2018) (3)
Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. (2018) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
“Aerobic glycolytic imaging” of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging (2021) (3)
Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas (2022) (3)
Scientific Program 2012 ISEV meeting Wednesday 18th April (2012) (3)
Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma. (2012) (3)
Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2010) (3)
Extent of Glioma Resection Using Lowfield ( 0 . 2 T ) versus High-field ( 1 . 5 T ) Intraoperative MRI and Image-guided Frameless Neuronavigation (2014) (3)
IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma (2007) (3)
Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab (2020) (2)
Preferential tumor localization in relation to 18F-FDOPA uptake for lower‐grade gliomas (2021) (2)
Recognized focused practice: Does sub-specialty designation offer value to the neurosurgeon? (2017) (2)
ATIM-25. NEOADJUVANT PD-1 ANTIBODY BLOCKADE IS ASSOCIATED WITH FOCAL UPREGULATION OF PD-L1 AND CD8 T CELL INFILTRATE IN RECURRENT GLIOBLASTOMA (2018) (2)
Diversity in Neurosurgical Recruitment and Training in the United States: A Systematic Review. (2022) (2)
ATIM-02. SUCCESSFUL CANCER-SELECTIVE GENE DELIVERY FOLLOWING INTRAVENOUS TOCA 511 DELIVERY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (HGG) (2016) (2)
325 Maintenance of Certification and the Aging Neurosurgeon. (2016) (2)
Continuous improvement in patient safety and quality in neurological surgery: the American Board of Neurological Surgery in the past, present, and future. (2020) (2)
ATIM-32. PHASE IIA CLINICAL TRIAL EVALUATING DENDRITIC CELL VACCINE FOR THE TREATMENT OF LOW-GRADE GLIOMAS (2016) (2)
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION (2018) (2)
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
Abstract 2491: Treatment with tumor lysate-pulsed autologous dendritic cells prolongs survival in patients with recurrent glioblastoma multiforme (2015) (2)
American Association for Cancer Research Genetics and Biology of Brain Cancers 2009, December 13–15, 2009, San Diego, CA (2010) (2)
Neurosurgical and Other Treatment Options for Metastatic Melanoma in the Central Nervous System: Part II (2005) (1)
Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune-Based Therapies and Developing Clinical Trials (2018) (1)
Omics and Prognostic Markers (2010) (1)
BIOM-31. PROGNOSTIC VALUE OF MGMT METHYLATION IN IDH MUTANT GLIOMAS (2020) (1)
Abstract 767: TCR sequencing can identify and track tumor-specific T cell populations and is a predictive biomarker of response to DC vaccination in glioblastoma patients (2016) (1)
Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma (2020) (1)
NI-32ENHANCING TUMOR RESPONSE USING QUANTITATIVE VOLUMETRY FROM T1 SUBTRACTION MAPS IN MALIGNANT GLIOMA TREATED WITH DENDRITIC CELL VACCINATION (2014) (1)
NIMG-25IMPROVED LEAKAGE CORRECTION FOR DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI ESTIMATES OF RELATIVE CEREBRAL BLOOD VOLUME (rCBV) IN HIGH-GRADE GLIOMAS BY ACCOUNTING FOR BIDIRECTIONAL CONTRAST AGENT EXCHANGE (2015) (1)
ATIM-21. INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH HIGH GRADE GLIOMA RESULTS IN QUANTIFIABLE EXPRESSION OF CYTOSINE DEAMINASE IN TUMOR TISSUE. (2017) (1)
NCMP-01. SEIZURE CONTROL AFTER INITIAL PRESENTATION IN IDH MUTATED GLIOMA PATIENTS (2017) (1)
Targeted Public Health Training for Neurosurgeons: An Essential Task for the Prioritization of Neurosurgery in the Evolving Global Health Landscape (2022) (1)
A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration (2022) (1)
The Dopamine Receptor Antagonist TFP Prevents Phenotype Conversion and Improves Survival in Mouse Models of Glioblastoma (2019) (1)
Dendritic Cell Vaccination is Effective Against H3.3G34R Mutant Glioblastoma in a Novel Syngeneic Genetically Engineered Mouse Model (2020) (1)
ATIM-05. COMPLEMENTARY CLINICAL AND ANCILLARY DATA FROM 123 PATIENTS WITH RECURRENT HIGH GRADE GLIOMA FROM THREE PHASE 1 TRIALS OF TOCA 511 AND TOCA FC: UPDATE AND JUSTIFICATION FOR A PHASE 2/3 TRIAL (2016) (1)
Editors’ Message to the Readership (2007) (1)
PATH-17. CORRELATION OF COMMERCIALLY-AVAILABLE QUANTITATIVE MGMT (O-6-METHYLGUANINE-DNA METHYLTRANSFERASE) METHYLATION SCORES AND OVERALL GBM PATIENT SURVIVAL (2017) (1)
IMCT-10A PHASE I DOSE ESCALATION STUDY TO TEST THE SAFETY OF INTRATUMORAL ADOPTIVE IMMUNE THERAPY WITH AlloCTL IN RECURRENT GLIOMA PATIENTS. (2015) (1)
Development of an integrated practice unit: Utilizing a lean approach to impact value of care for brain tumor patients. (2016) (1)
ATIM-26. PD-1 EXPRESSION BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMA IS A MARKER OF BOTH ACTIVATION AND EXHAUSTION (2016) (1)
Association of aggressive resection with survival and progression-free survival in adult low-grade glioma: A systematic review and meta-analysis with numbers needed to treat. (2017) (1)
Amine-weighted chemical exchange saturation transfer (CEST) MRI in brain tumors. (2022) (1)
Neoplasm Gliomas: advances in molecular analysis and characterization (2005) (1)
Autocrine endothelin-3 / endothelin receptor B signaling maintains cellular and molecular properties of tumorigenic glioblastoma stem cells (2011) (1)
Acknowledgement of Reviewers 2012 (2013) (1)
Glioblastoma: Molecular Mechanisms and Clinical Trials. (2021) (1)
Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. (2017) (1)
Introduction: brain tumor immunotherapy (2015) (1)
Risk factors for platelet transfusion in glioblastoma surgery (2018) (1)
LGG-01. NF1 MUTATION DRIVES NEURONAL ACTIVITY-DEPENDENT OPTIC GLIOMA INITIATION (2021) (1)
Editorial. Sexual harassment in neurosurgery: #UsToo. (2020) (1)
Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study (2022) (1)
Benefit of MGMT methylation in glioblastoma in relation to hTERT promoter mutation. (2016) (1)
CLIN-IMMUNOTHERAPY/BIOLOGIC THERAPIES (2012) (1)
Abstract 3308: Endothelin 3/endothelin receptor B signaling pathway blockade depletes radio-chemoresistant glioblastoma stem cells (2011) (0)
Spectro-Temporal Autofluorescence Contrast–Based Imaging for Brain Tumor Margin Detection and Biobanking (2017) (0)
Autologous tumor-lysate pulsed dendritic cell vaccination, together with the TLR-7 agonist 5% imiquimod, and serum pro- inflammatory cytokine levels in glioblastoma patients (2008) (0)
Qualitative detection of ceramide and other metabolites in brain tumor by localized correlated spectroscopy (2009) (0)
Books Received (2001) (0)
Presentation Title: Neural stem cells, brain tumors, and brain tumor stem cells (2008) (0)
TMIC-16. TUMOR-INFILTRATING MYELOID CELLS MEDIATE ADAPTIVE IMMUNE RESISTANCE IN GLIOBLASTOMA (2016) (0)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma (2019) (0)
Abstract 4749: Genetic signature of malignant glioma is associated with responsiveness to autologous tumor lysate-pulsed dendritic cell vaccination + TLR agonists (2010) (0)
DDRE-23. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO LIPID PEROXIDATION INDUCED CELL DEATH (2021) (0)
Active immunotherapy in glioma: Focus on cell-based approaches (2012) (0)
MART-1 Adenovirus-Transduced Dendritic Cell Immunization in a Murine Model of Metastatic Central Nervous System Tumor (2004) (0)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (0)
Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities (2018) (0)
Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide (2015) (0)
EPIG-11THE IMPLICATION OF CpG island AND SPINT2 HYPERMETHYLATION IN BOTH IDH1 WILD-TYPE AND MUTANT ADULT DIFFUSE GLIOMAS (2015) (0)
Abstract 3765: High-throughput RNAi screening identifies genes controlling glioblastoma stem cell migration and survival. (2013) (0)
TAMI-26. INVESTIGATING TUMOR MICROENVIRONMENT METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2021) (0)
HIGH GRADE GLIOMAS AND DIPG (2014) (0)
Immune Checkpoint Inhibitors Remodel the Immune Microenvironment in Brain Metastases and Promote T Cell Infiltration (2020) (0)
Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas for Future Targeted Therapies (2012) (0)
Listeria monocytogenes Anti-Melanoma Effects of a Recombinant The TLR 7 Agonist Imiquimod Enhances the Prins (2005) (0)
Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model (41.35) (2009) (0)
Developing a professionalism and harassment policy for organized neurosurgery. (2021) (0)
Cancer Genes and Genomics Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells (2011) (0)
787 Phase III clinical trial to test the safety and efficacy of autologous tumor lysate-loaded dendritic cells in patients with newly diagnosed glioblastoma (2020) (0)
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Patient Serum With Glioma and Cerebrospinal Fluid Extracellular Vesicles (2013) (0)
Title Stem cell associated gene expression in glioblastoma multiforme : relationship to survival and the subventricular zone Permalink (2010) (0)
Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment (2018) (0)
315 Molecular signature of the PTEN tumor suppressor-identification of IGFBP2 as a surrogate marker for PTEN/Akt signaling (2004) (0)
EXTH-87. DECITABINE POTENTIATES MENINGIOMA IMMUNOTHERAPY TARGETING NY-ESO-1 (2022) (0)
IMMU-20. SINGLE-CELL RNASEQ OF TUMOR INFILTRATING IMMUNE CELLS FROM NEOADJUVANT ANTI-PD1 TREATED GBM PATIENTS REVEALS GLOBAL TRANSCRIPTIONAL CHANGES AND IMMUNOSUPPRESSIVE ADAPTIVE RESPONSES BY MYELOID CELLS (2020) (0)
Analysis of 223 Brain Tumor Patients Treated at a Level 1 Trauma County Medical Center (2012) (0)
TAMI-06. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2020) (0)
IMMU-28. HIGH-DIMENSIONAL SINGLE CELL CHARACTERIZATION OF THE SYSTEMIC INFLUENCE OF NEOADJUVANT PD-1 BLOCKADE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2018) (0)
O 6-2 Morphometric study of myelinated fibers in sural nerve of transthyretin familial amyloid neuropathy asymptomatic carriers : back to the archives of the Corino de Andrade Unit (2018) (0)
Abstract 3727: Overcoming of radiochemoresistance in glioblastoma stem cells via inhibition of lipid catabolism and SIRT1 deacetylase. (2013) (0)
TAMI-48. ENGRAFTMENT PHENOTYPES IN PRECLINICAL MODEL SYSTEMS REVEAL A FUNCTIONAL SUBGROUP OF PATIENT TUMORS DEPENDENT ON THE BRAIN TUMOR MICROENVIRONMENT FOR GROWTH (2020) (0)
BIMG-11. PHARMACODYNAMIC EVALUATION OF IDH AND EGFR INHIBITION IN HUMAN GLIOMAS USING MOLECULAR MRI (2021) (0)
Combined analysis of O 6 -methylguani ne-DNA methyltransferase protein expression and promoter methyl ation provides opti mized prognosticati on of gli oblastoma outcome NEURO- ONCOLOGY (2015) (0)
Cellular and Molecular Properties of Glioblastoma Stem Cells Autocrine Endothelin-3 / Endothelin Receptor B Signaling Maintains (2011) (0)
Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination (2020) (0)
Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat. (2017) (0)
IMMU-21. MULTIDIMENSIONAL CHARACTERIZATION OF IMMUNE CELL POPULATIONS IN THE GLIOMA TUMOR MICROENVIRONMENT REVEALS A DOMINANT PROPORTION OF CELLS DERIVED FROM THE MYELO-MONOCYTIC LINEAGE (2018) (0)
Radial mobility and cytotoxic function of retroviral replicating vector transduced, non-adherent alloresponsive T lymphocytes. (2015) (0)
CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
Combined Treatment with Dopamine Receptor Antagonists and Radiation Creates a Metabolic Vulnerability in Mouse Models of Glioblastoma (2020) (0)
A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients (2023) (0)
ASPM Analysis of oncogenic signaling networks in glioblastoma identifies (2006) (0)
P10.03 Management of low-grade glioma: a systematic review and meta-analysis. (2017) (0)
ETMM-02. PRECLINICAL MODELS REVEAL BRAIN-MICROENVIRONMENT SPECIFIC METABOLIC DEPENDENCIES IN GLIOBLASTOMA (2021) (0)
214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques (2018) (0)
IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS (2015) (0)
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL (0)
CBIO-25. INTEGRATED MOLECULAR AND BH3 PROFILING OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA (2020) (0)
NIMG-45. DIFFUSION MRI AS AN EARLY BIOMARKER OF OVERALL SURVIVAL BENEFIT IN RECURRENT GLIOBLASTOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS (2021) (0)
277 EPIGENETIC MODIFICATIONS OF CANCER ANTIGEN EXPRESSION IN GLIOMAS. (2007) (0)
Retrospective examination of pseudoprogression in IDH mutant gliomas (2023) (0)
Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation (2022) (0)
TMIC-26. PRECLINICAL MODEL SYSTEMS OF GLIOBLASTOMA REVEAL MICROENVIRONMENTAL PROGRAMS AND DEPENDENCIES IN PATIENT TUMORS (2019) (0)
PATH-16. COMPREHENSIVE GENOMIC PROFILING ACCURATELY DETERMINES 1p19q CODELETION STATUS IN GLIOMAS (2020) (0)
TMIC-19. NEURODEVELOPMENTAL SUBTYPES SHAPE LIPID METABOLIC REPROGRAMMING IN GLIOMAS (2022) (0)
CBIO-03. A COMPREHENSIVE CHARACTERIZATION OF THE GBM LIPIDOME REVEALS A MOLECULARLY-DEFINED SUB-GROUP WITH HEIGHTENED SENSITIVITY TO FERROPTOSIS (2021) (0)
Gliomas: advances in molecular analysis and characterization. Commentary (2005) (0)
Pediatric Medulloblastoma: Pituitary Adenylyl Cyclase Activating Peptide/Protein Kinase A Antagonism of Hedgehog Signaling (2012) (0)
Glioblastoma, Part II: Molecular Targets and Clinical Trials (2021) (0)
Model T Cells in a Melanoma + Primed CD8 - IL-12 Regulates the Clinical Responsiveness of Enhanced Sensitivity to IL-2 Signaling (2011) (0)
Engineering T Cell Receptors to Target H3.3G34 Mutant Glioblastoma (2020) (0)
TMIC-02. PRE-SURGICAL IMMUNE CHECKPOINT BLOCKADE RESHAPES THE IMMUNE LANDSCAPE AND SPATIAL ARCHITECTURE OF METASTATIC BRAIN TUMORS (2022) (0)
NIMG-36. DELINEATION OF IMMUNE RESPONSES AFTER IMMUNOTHERAPY IN GLIOBLASTOMA USING PET AND MRI (2017) (0)
Next-Generation Sequencing and Personalized Medicine for Brain Cancer (2018) (0)
CTIM-27. AUTOLOGOUS TUMOR LYSATE-LOADED DENDRITIC CELL VACCINATION IMPROVES SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: SURVIVAL RESULTS FROM A PHASE 3 TRIAL (2022) (0)
CBMT-44. COMPREHENSIVE CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY REVEALS THE MOLECULAR BLOCKS RESPONSIBLE FOR RESISTANCE TO CELL DEATH IN GLIOBLASTOMA (2019) (0)
NIMG-50. ASSOCIATION BETWEEN SALINITY, ACIDITY, DIFFUSIVITY, AND HYPOXIA IN HUMAN GLIOMAS USING MULTI-NUCLEAR MRI (2022) (0)
TAMI-69. NF1 MUTATION DRIVES NEURONAL ACTIVITY-DEPENDENT OPTIC GLIOMA INITIATION (2021) (0)
NIMG-49. VALIDATION OF SIMULTANEOUS PH- AND O2-WEIGHTED MOLECULAR MRI USING 18F-FDG PET, IMMUNOHISTOCHEMISTRY, AND BIOENERGETICS (2020) (0)
25 Durable complete responses observed in patients with recurrent high grade glioma treated with Toca 511 & Toca FC (2018) (0)
Single Cell Sequencing of Image Guided Biopsies Identifies Spatial and Temporal Heterogeneity in High Grade Glioma (2020) (0)
CBIO-27. INTEGRATED FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF THE INTRINSIC APOPTOTIC MACHINERY IDENTIFIES THERAPEUTIC VULNERABILITIES IN GLIOBLASTOMA (2021) (0)
ATPS-62TARGETING OF NOVEL GBM BIOMARKER EMP2 RESULTS IN DECREASED TUMOR GROWTH AND INCREASED TUMOR NECROSIS (2015) (0)
It-007. Cytotoxic T Cell Functional Responsiveness May Predict Clinical Efficacy Of Dendritic Cell Vaccination In Glioblastoma Patients (2013) (0)
Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease (2022) (0)
Enhanced IL-2 signaling renders IL-12 primed CD8+ T-cells superior in adoptive immunotherapy. (131.20) (2010) (0)
Overview of Dendritic Cell Vaccines for Brain Tumors (2018) (0)
Improving care coordination for brain tumor patients through value-based care redesign of a virtual integrated practice unit. (2017) (0)
Anti-tumor activity and trafficking of self , tumor-specific T cells against tumors located in the brain , a , b (2009) (0)
CHAPTER 7 BEAMing qRT-PCR analysis of mutant IDH 1 mRNA in tumormicrovesicles (2012) (0)
Characterizing malignant transformation in patients with IDH-mutant glioma. (2022) (0)
ACTR-54. VIGILANT OBSERVATION OF GLIADEL WAFER IMPLANT (VIGILANT) REGISTRY: INTERIM ANALYSIS (2019) (0)
IMST-56. TUMOR LYSATE-PULSED DC VACCINATION INDUCES NEOANTIGEN-SPECIFIC T CELL RESPONSES (2016) (0)
ATIM-16. VALIDATION OF RESPONSE TO NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA (2019) (0)
Current Status of Immunotherapeutic Strategies for Central Nervous System Tumors (2006) (0)
NIMG-60. IDH MUTANT GLIOMAS WITH 1p/19q CO-DELETION ARE LESS ACIDIC THAN NON-CO-DELETED GLIOMAS AS MEASURED WITH PH-WEIGHTED AMINE CEST-MRI AND AMINO ACID PET (2019) (0)
IMST-28. NON-INVASIVE IMMUNE MONITORING FOLLOWING DC VACCINATION EFFECTIVELY DELINEATES IMMUNE RESPONSES IN GLIOBLASTOMA (2016) (0)
Proteins and Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. (2015) (0)
TMOD-03. GLIOMAPDOX: A MOLECULARLY DIVERSE LIBRARY OF DIRECT-FROM-PATIENT ORTHOTOPIC GLIOMA XENOGRAFTS RECAPITULATES INTRATUMOR HETEROGENEITY (2018) (0)
IMMU-37. VEMURAFENIB ENHANCES THE CYTOTOXICITY OF NY-ESO-1 TCR ENGINEERED T-CELLS FOR BRAF MUTANT BRAIN TUMORS (2018) (0)
NIMG-36. VISUALIZATION OF TUMOR HETEROGENEITY AND PREDICTION OF ISOCITRATE DEHYDROGENASE MUTATION STATUS FOR HUMAN GLIOMAS BY USING MULTIPARAMETRIC PHYSIOLOGIC AND METABOLIC MRI (2021) (0)
A Cellular Immunotherapy Research Study for Brain Cancer (2012) (0)
EPCO-10. INTRATUMORAL HETEROGENEITY OF ENVIRONMENT-INDUCED EXPRESSION PROGRAMS IN GLIOMA PATIENTS AND DERIVED MODEL SYSTEMS (2021) (0)
Mutation in isocitrate dehydrogenase 1 ( IDH 1 ) leads to increased T 2 , ADC and decreased lactate and glutamate in glioblastoma model (2012) (0)
Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry (2019) (0)
Immunity Central Nervous System Antitumor Antigen-Specific T Cell Priming : Relation to Dendritic Cell Survival and Promotes Tumor The TLR-7 Agonist , Imiquimod , Enhances (2005) (0)
198 An Antigen Vault Nanoparticle Vaccine Can Effectively Stimulate Dendritic Cells and Activate a Specific T cell Immune Response. (2012) (0)
IMMU-33. IMMUNE PROFILING REVEALS INHIBITORY MACROPHAGES AND A DISTINCT SPATIAL DISTRIBUTION OF IMMUNE CELLS IN DIFFERENT TYPES OF BRAIN METASTASES (2019) (0)
GENE-41. EPIGENETIC DOWN-REGULATION OF THE METALLOTHIONEIN FAMILY IN ISOCITRATE DEHYDROGENASE (IDH) MUTANT GLIOMAS (2017) (0)
Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients (2012) (0)
SCDT-06. QUANTIFIABLE LEVELS OF THE TRANSGENE, CYTOSINE DEAMINASE, IN TUMOR SAMPLES FOLLOWING INTRAVENOUS DELIVERY OF TOCA 511 IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2017) (0)
IT-01PD1/PDL1 INTERACTIONS MEDIATE SUPPRESSION OF ANTI-TUMOR IMMUNE ACTIVITY IN GLIOMA (2014) (0)
CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS (2020) (0)
NIMG-54. AMINE CEST MRI, A FAST AMINO ACID AND PH-WEIGHTED MOLECULAR IMAGING TECHNIQUE, CORRELATES WITH 18F-FDOPA PET AND IMAGE-GUIDED BIOPSY IN HUMAN GLIOMA (2016) (0)
Genetically Engineered T Cell Immunotherapy for Gliomas and Other Solid Tumors (2015) (0)
IMMU-20. CHARACTERIZING THE IMMUNE LANDSCAPE OF PD-1/PD-L1 IN BRAIN TUMOR IMMUNE CELL POPULATION USING CyTOF MASS CyTOMETRY (2017) (0)
TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT (2015) (0)
TMIC-06. MYELOID POPULATIONS AND THE EFFECT OF NEOADJUVANT PD-1 INHIBITION IN THE GLIOBLASTOMA MICROENVIRONMENT: A SURFACEOMIC AND TRANSCRIPTOMIC DISSECTION AT THE SINGLE-CELL LEVEL (2019) (0)
Assessment of treatment response to dendritic cell vaccine in patients with glioblastoma using a multiparametric MRI-based prediction model. (2023) (0)
EXTH-11. COLD ATMOSPHERIC PLASMA SELECTIVELY INDUCES APOPTOSIS AND FERROPTOSIS THROUGH REACTIVE OXYGEN SPECIES IN HIGH-GRADE GLIOMA (2021) (0)
IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA (2019) (0)
Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas (2021) (0)
Dendritic Cell Therapy for Brain Tumors (2017) (0)
Abstracts IMMUNOTHERAPY / BIOLOGICAL THERAPIES IT-001. FEASIBILITY OF LYMPHOCYTE HARVESTING AND REINFUSION IN PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS (2013) (0)
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma (2014) (0)
Abstract 447: The IDH1 mutation in human glioblastoma and its effects on epigenetic modification and cell fate selection (2014) (0)
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma (2018) (0)
Protect Cancer Cells from Lipotoxicity An Essential Requirement for the SCAP / SREBP Signaling Axis to (2013) (0)
Prognostic Factors for Tumor Control Following Surgical Resection and Adjuvant Radiotherapy for Intracranial Chordomas (2013) (0)
Histone deacetylase inhibitor, LBH589, synergizes with an immunotherapy treatment in an in vivo murine brain tumor model (2009) (0)
Decorin Expression Is Associated With Diffusion MR Phenotypes in Glioblastoma (2019) (0)
CBIO-05. LIPID METABOLIC REPROGRAMMING SENSITIZES A MOLECULARLY-DEFINED SUBSET OF GLIOBLASTOMAS TO FERROPTOSIS (2020) (0)
BI-10pH-WEIGHTED MRI IN HUMAN GLIOMAS (2014) (0)
LAB-IMMUNOLOGY RESEARCH (2012) (0)
NIMG-41. PH-WEIGHTED MOLECULAR MRI AS AN EARLY BIOMARKER OF METABOLIC RESPONSE TO IDH INHIBITION IN IDH MUTANT GLIOMAS (2021) (0)
NIMG-55. SIMULTANEOUS QUANTITATIVE PH MAPPING AND HYPOXIA IMAGING USING FAST MULTI-ECHO AMINE CEST-EPI IN HUMAN GLIOMAS (2016) (0)
ACTR-53. SAFETY AND EFFICACY EVALUATION OF A PHASE II STUDY OF BORTEZOMIB IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) (2017) (0)
Adjuvant inhibition of iAPC function in the tumor microenvironment promotes therapeutic immunity in the setting of vaccination-induced T cell anti-tumor response (2015) (0)
NIMG-59. VALIDATION OF QUANTITATIVE VESSEL SIZE IMAGING (VSI) IN HUMAN GLIOMAS USING IMAGE-GUIDED STEREOTACTIC BIOPSIES (2018) (0)
SURG-21. CASE-MATCHED STUDY OF EFFECT OF INTRA-OPERATIVE MRI ON EXTENT OF RESECTION AND CLINICAL OUTCOME IN GLIOMA PATIENTS UNDERGOING SURGICAL RESECTION (2016) (0)
NIMG-44. PROGNOSTIC VALUE OF PH- AND OXYGEN-SENSITIVE MRI IN GLIOMA PATIENTS (2021) (0)
ii ABSTRACT OF THE DISSERTATION Using Patient-Derived Gliomaspheres to Molecularly Characterize and Dissect Distinctive Traits of IDH1 Mutant Gliomas for Therapeutic Benefit by (2016) (0)
EPIGENETIC MODIFICATIONS OF CANCER ANTIGEN EXPRESSION IN GLIOMAS.: 277 (2007) (0)
Toca 511 & Toca FC: Evaluation of Durable Response Rate in the Post-Resection Setting and Association with Survival in Patients with Recurrent High Grade Glioma (S23.006) (2018) (0)
IMPS-19RETROVIRAL REPLICATING VECTOR-MEDIATED DELIVERY OF AN IMMUNODOMINANT NEO-ANTIGEN EPITOPE TARGET FOR VIRO-IMMUNOTHERAPY IN EXPERIMENTAL GLIOMA. (2015) (0)
325 Maintenance of Certification and the Aging Neurosurgeon. (2016) (0)
Generation of a molecular interactome of the glioblastoma perivascular niche reveals Integrin Binding Sialoprotein as a key mediator of tumor cell migration (2021) (0)
Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI (2022) (0)
NIMG-48. MULTI-ECHO SPIN-AND-GRADIENT ECHO (SAGE) PERFUSION MRI TO EVALUATE BRAIN TUMOR MICROSTRUCTURE AND MICROVASCULATURE (2022) (0)
ACTR-06. THE TOCA 7 STUDY: PHASE 1B STUDY OF TOCA 511, A LIVE GAMMA RETROVIRUS, AND TOCA FC, AN EXTENDED-RELEASE FORMULATION OF 5-FLUOROCYTOSINE COMBINED WITH STANDARD OF CARE IN NEWLY DIAGNOSED HIGH GRADE GLIOMA (NCT02598011) (2016) (0)
Prognostic value of MGMT methylation in IDH mutant gliomas (2022) (0)
Abstract 5559: Proteomic identification of activated, essential tyrosine kinases in human cancers (2010) (0)
CBMT-43. INTEGRATED LIPIDOMIC AND MOLECULAR ANALYSIS REVEALS A SUBSET OF GLIOBLASTOMA VULNERABLE TO FERROPTOSIS (2019) (0)
IMMU-02. NEOANTIGENS ARISING FROM ALTERNATIVE SPLICING EVENTS MAY BE TARGETED BY TUMOR INFILTRATING LYMPHOCYTES IN GLIOBLASTOMAS (2019) (0)
Quantitati ve probabil istic functional diffusion mappi ng i n newly diagnosed gl ioblastoma treated w i th radiochemotherapy (2015) (0)
TMIC-40. TRANSCRIPTOMIC CHARACTERIZATION OF PATIENT GLIOMAS AND DERIVED MODEL SYSTEMS REVEALS ENVIRONMENTAL INFLUENCE ON NEURODEVELOPMENTAL CELLULAR STATES (2022) (0)
MPTH-27A LARGE-SCALE UCLA GLIOMA TISSUE MICROARRAY IDENTIFIES EMP2 AS A NOVEL BIOMARKER FOR GBM THAT CORRELATES WITH OVERALL PROGNOSIS (2015) (0)
NIMG-56. PATTERNS FROM DYNAMIC VESSEL SIZE IMAGING OF ARTERIAL AND VENOUS PERFUSION CORRELATES WITH AGGRESSIVENESS AND STRATIFIES 1p19q CO-DELETED FROM NON-CODELETED LOW-GRADE GLIOMAS (2016) (0)
STEM-05. SINGLE CELL SEQUENCING CHARACTERIZES SPATIAL AND TEMPORAL RELATIONSHIPS OF ENHANCING AND NON-ENHANCING REGIONS IN HIGH-GRADE GLIOMA (2020) (0)
Handbook of brain tumor chemotherapy, H.B. Newton (Ed.). Academic Press, Elsevier Inc., San Diego (2005), 510 pp; Rating: **** Recommended audience: Neurosurgeons, neuro-oncologists, neuroscientists, general practitioners, ISBN: 0-12-088410-0☆ (2006) (0)
Single-cell analysis characterizes non-enhancing region of recurrent high-grade glioma (2022) (0)
NIMG-15. DIFFERENTIATION OF IDH1 MUTANT AND WILD TYPE GLIOMAS USING pH- AND OXYGEN-SENSITIVE MOLECULAR MRI (2018) (0)
791 Extent of Brain Tumor Resection Using High-field (1.5-T) versus Low-field (0.2-T) Intraoperative Magnetic Resonance Imaging (2004) (0)

This paper list is powered by the following services:

Other Resources About Linda Liau

en.wikipedia.org

What Schools Are Affiliated With Linda Liau?

Linda Liau is affiliated with the following schools: